(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Matt Savino, Carlyle global head of capital markets, expects the IPO market to improve in 2025. He is on "Bloomberg ." ...

BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...

The Carlyle Group Inc. (NASDAQ:CG), a global investment firm with a market capitalization of $18.52 billion, has recently ...

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global ...

The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...

Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...

Carlyle completed the acquisition through a proprietary and exclusive transaction. The investment will come from funds ...

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...

Carlyle Group Inc. completed its acquisition of a controlling stake in an Indian auto-parts making platform formed by the ...